Literature DB >> 7069531

Galactose intolerance in individuals with double heterozygosity for Duarte variant and galactosemia.

H P Schwarz, K A Zuppinger, A Zimmerman, H Dauwalder, R Scherz, D M Bier.   

Abstract

The most frequent cause for an abnormal result during screening of newborn infants for galactosemia is double heterozygosity for Duarte variant and galactosemia, in which galactose-1-phosphate uridyl transferase activity is reduced to approximately 17% of normal. Thirty-nine oral galactose tolerance tests were performed in 27 infants and children with this condition. In comparison to age-matched controls, all children with this genetic variant reached much higher levels of blood galactose and galactose-1-phosphate following oral galactose challenge. The integrated plasma galactose response increased with the age of the child, whereas integrated erythrocyte galactose-1-phosphate responses were elevated to the same degree at all ages. Although all children appeared clinically normal, the marked abnormalities in the ability to dispose of ingested galactose raise questions concerning appropriate dietary recommendations for such children.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7069531     DOI: 10.1016/s0022-3476(82)80568-4

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  4 in total

1.  Komrower Lecture. Galactosaemia today: the enigma and the challenge.

Authors:  S Segal
Journal:  J Inherit Metab Dis       Date:  1998-08       Impact factor: 4.982

2.  Development of a protocol for newborn screening for disorders of the galactose metabolic pathway.

Authors:  F G Bowling; A R Brown
Journal:  J Inherit Metab Dis       Date:  1986       Impact factor: 4.982

3.  Polymorphism of erythrocyte galactose-1-phosphate uridyltransferase among Chinese.

Authors:  Y K Xu; W G Ng
Journal:  Hum Genet       Date:  1983       Impact factor: 4.132

Review 4.  Partial deficiency of galactose-1-phosphate uridyltransferase.

Authors:  R Gitzelmann; N U Bosshard
Journal:  Eur J Pediatr       Date:  1995       Impact factor: 3.183

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.